Express | Sword refers to neurological diseases that plague tens of millions of patients, Xinrui has received 80 million US dollars to promote two clinical treatments

▎The editor of WuXi AppTec's content team today, Eliem Therapeutics announced that it has stepped out of the hidden model.
The company established in 2019 has so far received US$80 million in financing.

The company's goal is to treat chronic pain, depression, epilepsy and anxiety and other neurological diseases by regulating the excitability of neurons.

These diseases plague tens of millions of patients every day.

Currently the company has two candidate therapies into clinical trials.

Eliem's ​​main candidate therapy is called ETX-810, which is a potential "first-in-class" non-opioid oral prodrug (prodrug) for the treatment of chronic pain.

After it is decomposed in the body, it can increase the level of palmitoylethanolamide (PEA).
PEA has the function of extensively regulating neuroinflammation and pain signaling pathways.
In chronic pain patients, the synthesis of PEA is reduced and the metabolism is increased, resulting in insufficient control of PEA levels.
Nerve inflammation and pain.

ETX-810 can reduce neuroinflammation and pain by increasing the level of PEA.

The design of the prodrug greatly improves the oral bioavailability of the drug, thereby maximizing the efficacy.

It is currently used in phase 2a clinical trials for the treatment of sciatica and diabetic peripheral neuralgia.

▲ETX-810 reduces neuroinflammation and pain by increasing PEA levels (picture source: Eliem's ​​official website) The company's other clinical phase research therapy ETX-155 is a new generation of oral GABAA receptor positive allosteric modulation Agent.

It can regulate the activity of GABAA receptors inside and outside synapses of nerves, enhance GABA-mediated inhibitory signals, and thereby reduce the level of neuronal excitement.

It can be used to treat epilepsy, depression, and hormone-related mood disorders.

Eliem believes that it has "best-in-class" potential.

▲The mechanism of action of ETX-155 (picture source: Eliem's ​​official website) "Most patients with chronic pain and other diseases caused by uncontrolled neuronal excitability have not been able to effectively control their symptoms with existing therapies, and even prevent them from completing daily activities.
.

"Eliem president and CEO Bob Azelby said," I believe we have an experienced and dedicated team will be able to develop a better clinical outcome of therapy for them, giving them the opportunity to resume a normal life.

"reference Source: [1] Eliem Therapeutics Emerges from Stealth with $80 Million Invested to Progress Multiple Clinical Stage Assets Targeting Neuronal Excitability Disorders.
Retrieved March 25, 2021, from emerges-from-stealth-with-80-million-invested-to-progress-multiple-clinical-stage-assets-targeting-neuronal-excitability-disorders-301255348.
html.
Note: This article aims to introduce medical and health research progress, not Recommended treatment plan.

If you need guidance on treatment plans, please go to a regular hospital for treatment.